About
NWPharmaTech
NWPharmaTech is the pharmaceutical sponsor for this investigational clinical high-risk for psychosis (CHR-P) research programme. We publish public information about the science and how the work is organised — without presenting unfinished work as live investment or clinical enrolment.
Company identity
Corporate identity: nwpharmatech.com. This site (www.nwpharmatech.org) is the public information home for the CHR-P initiative.
As sponsor, NWPharmaTech remains accountable for clinical development, safety, manufacturing quality (CMC), and regulatory strategy related to the programme. Investigators, ethics committees, and regulators retain their independent roles.
People
Named leadership and programme profiles are published on the Team page, organised as corporate leadership, scientific programme expertise, and company advisers. Professor Scott Woods is listed as CHR-P programme lead in an individual capacity. See Team for affiliation notes.
What this site is not
- Not medical advice, a diagnosis service, or a crisis line
- Not a trial enrolment portal
- Not an offer to sell securities or any investment interest — financing interfaces stay inactive on this public site